
[BNews]
Current Articles
Novo Nordisk’s Obesity Setback: What Kagrama’s Miss vs. Zepbound Means for Investors
A surprising obesity trial result has shaken confidence in Novo Nordisk (NVO +1.38%) and sharpened the spotlight on Eli Lilly (LLY 2.03%) in this fiercely competitive GLP‑1 race. Watch the video below to see what it could mean for investors. *This video was published on Feb.24, 2026. Andy Cross has no position in any of...
Novo Nordisk’s Obesity Setback: What Kagrama’s Miss vs. Zepbound Means for Investors
Bitcoin rebound appears a ‘relief rally,’ not the start of a new bullish cycle, says CryptoQuant
"Bitcoin is still inside a bear market, despite the recent price rally," Julio Moreno, head of research at CryptoQuant, said.




